<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04107207</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001101</org_study_id>
    <nct_id>NCT04107207</nct_id>
  </id_info>
  <brief_title>Evaluating the Effects of Kombucha as a Hyperglycemic Therapeutic Agent Within Diabetic Human Subjects</brief_title>
  <official_title>Pilot Study to Evaluate Effects of Kombucha as a Hyperglycemic Therapeutic Agent Within Diabetic Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study's primary objective is to determine the ability of Kombucha to impact blood sugar
      levels in patients with diabetes mellitus type II. The secondary objective is to determine
      the ability of Kombucha to impact blood pressure, and quality of life measures as measured by
      uniform questionnaire that includes: gut health, colds, infections, headaches, sleep, anxiety
      (GAD2), depression (PHQ2), skin health.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 11, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double blind crossover</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Sugar Levels</measure>
    <time_frame>10 weeks</time_frame>
    <description>outcome measure: mg/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gut health</measure>
    <time_frame>10 weeks</time_frame>
    <description>Worst ever | worse than usual | average | better than usual | best ever</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anxiety</measure>
    <time_frame>10 weeks</time_frame>
    <description>How often have you been bothered by the following problems? 6.1. Feeling nervous, anxious or on edge Not at all | Several days | More than half the days | Nearly every day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>depression</measure>
    <time_frame>10 weeks</time_frame>
    <description>How often have you been bothered by the following problems? 6.3. Little interest or pleasure in doing things Not at all | Several days | More than half the days | Nearly every day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skin health</measure>
    <time_frame>10 weeks</time_frame>
    <description>4.1. How would you rate your overall skin health? Worst ever | worse than usual | average | better than usual | best ever 5. How often do you experience skin problems such as dry skin, eczema, rashes, or acne? Not at all | Several days | More than half the days | Nearly every day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vulvovaginal health</measure>
    <time_frame>10 weeks</time_frame>
    <description>9.1. How would you rate your overall vulvovaginal health? Worst ever | worse than usual | average | better than usual | best ever</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Kombucha Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Either ginger kombucha or placebo ginger water will be given to subjects for weeks 1-4 and then the reciprocal beverage for weeks 6-10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Intervention</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Either ginger kombucha or placebo ginger water will be given to subjects for weeks 1-4 and then the reciprocal beverage for weeks 6-10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ginger Kombucha</intervention_name>
    <description>Craft Ginger Kombucha, a fermented black tea</description>
    <arm_group_label>Kombucha Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ginger Water</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. S/he is above the age of 18

          2. S/he has the ability to read, speak and write English

          3. S/he has telephone access

          4. S/he is diabetic and willing to check blood sugar levels every day

          5. Hb A1c &gt;7%

          6. Possesses a glucometer

        Exclusion Criteria:

          1. Allergy to kombucha ingredients

          2. Drinks kombucha regularly (&gt;3time per week)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Georgetown University MedStar Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 1, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

